☀️ Pitolisant Histamine H3 Receptor Antagonist Simulator

Baseline Histamine Tone

H3 autoreceptors quietly cap histamine release before treatment.

• 0.16 nM: H3 Autoreceptor Affinity (picomolar-range binding)
• ~70%: Baseline Autoreceptor Occupancy (tonic self-inhibition)
• ~64,000: Histaminergic Neurons (TMN) (human hypothalamus count)
• Low: Resting Wake Drive (untreated excessive sleepiness)

Negative feedback loop

H3 autoreceptors sense histamine and dampen further release.

Tuberomammillary origin

Histamine neurons cluster in the posterior hypothalamus.

Untreated sleepiness

Low histaminergic tone leaves patients drowsy all day.

Pitolisant Enters the Synapse

A single oral dose carries pitolisant to presynaptic H3 sites.

• 4.45–35.6 mg: Approved Dose Range (once daily, morning)
• ~3.5 h: Time to Peak (Tmax) (oral absorption)
• H3 ≫ H1/H2/H4: Receptor Selectivity (highly selective antagonist)
• Inverse agonist: Mechanism Class (blocks constitutive H3 activity)

Oral absorption

Pitolisant is swallowed and absorbed into the bloodstream.

Crossing the barrier

The drug crosses into the brain and reaches synapses.

Molecular targeting

Pitolisant molecules seek out presynaptic H3 autoreceptors.

H3 Autoreceptor Blockade

Bound drug molecules silence the histamine self-inhibition loop.

• ~75%: H3 Blockade at Standard Dose (receptor occupancy, peak)
• Disabled: Feedback Loop Status (no self-inhibition)
• ~20 h: Elimination Half-Life (sustained occupancy)
• Not scheduled: Abuse Potential (non-controlled substance)

Receptor occupancy

Drug molecules physically occupy the H3 binding pocket.

Feedback removed

Histamine can no longer tell neurons to slow down.

Disinhibition

Presynaptic neurons fire more freely once feedback is gone.

Increased Histamine Release

Freed from feedback, terminals push more histamine into the cleft.

• up to ~3×: Release Rate Increase (vs baseline tone)
• Elevated: Vesicle Fusion Events (presynaptic exocytosis)
• Sustained rise: Synaptic Histamine (through dosing interval)
• H1 (postsynaptic): Downstream Receptor (primary wake target)

More vesicles fuse

Disinhibited terminals release histamine more frequently.

Cleft concentration rises

Synaptic histamine levels climb steadily after dosing.

Postsynaptic binding

Released histamine binds H1 receptors on target neurons.

Enhanced Wakefulness

Sustained histaminergic tone keeps cortical circuits alert and engaged.

• Elevated: Wake-Promoting Signal (cortical arousal increase)
• Narcolepsy, EDS in OSA: Clinical Indications (FDA approved uses)
• Low: Stimulant-like Side Effects (mild headache, insomnia)
• None direct: Dopamine/Norepinephrine Action (non-stimulant profile)

Cortical activation

Increased histamine promotes arousal through H1 receptor signaling.

Wakefulness without stimulation

Alertness rises without amphetamine-like cardiovascular effects.

Clinical benefit

Patients report less daytime sleepiness across the dosing day.